Skip to main content
. Author manuscript; available in PMC: 2021 Jan 27.
Published in final edited form as: Int J Cancer. 2020 Jun 23;147(12):3550–3559. doi: 10.1002/ijc.33140

Figure 2.

Figure 2

Study outline and early relapse. Panel a shows the study outline containing 27 cycles (28 days per cycle) of DFMO therapy. Blood samples were collected at 3–4 cycle intervals as shown by the arrows indicating the most frequent time points at which samples were received. In each cycle, treatments were given once a week for the first 3 weeks followed by rest for 1 week prior to initiation of next cycle. Panels b, c, and d illustrate the number of patients who relapsed within 25 months, respective to the number CTCs detected at baseline (b) based on the consented patients whose samples were available at baseline (n=54), S1 (c) based on the consented patients whose samples were available at S1 (n=34), or those who maintained the indicated CTC levels through first 2 samples (d) based on the patients whose samples were available at either baseline or S1 (n=60), respectively.